<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453426</url>
  </required_header>
  <id_info>
    <org_study_id>109HV108</org_study_id>
    <nct_id>NCT01453426</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers</brief_title>
  <acronym>109HV108</acronym>
  <official_title>An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Adult Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, parallel-group study to evaluate the PK, safety, and tolerability of
      two different dose regimens of BG00012 over a 24-hour period to adult Chinese, Japanese, and
      Caucasian healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this healthy volunteer study is to provide pharmacokinetic and safety data for
      two different dose regimens of BG00012. The study will evaluate BG00012 administered over a
      24-hour period.

      The study will be conducted in male and female Chinese, Japanese, and Caucasian healthy
      volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of BG00012</measure>
    <time_frame>First dose to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of BG00012</measure>
    <time_frame>First dose to 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events, as a measure of safety and tolerability</measure>
    <time_frame>Subjects will be followed for the duration of the study, an expected 20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events, as a measure of safety and tolerability</measure>
    <time_frame>Subjects will be followed for the duration of the study, an expected 20 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Chinese Subjects - Dose 1 BG00012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chinese Subjects - Dose 2 BG00012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Subjects - Dose 1 BG00012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Subjects - Dose 2 BG00012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian Subjects - Dose 1 BG00012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian Subjects - Dose 2 BG00012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BG00012 Dose 1</intervention_name>
    <arm_group_label>Japanese Subjects - Dose 1 BG00012</arm_group_label>
    <arm_group_label>Chinese Subjects - Dose 1 BG00012</arm_group_label>
    <arm_group_label>Caucasian Subjects - Dose 1 BG00012</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BG00012 Dose 2</intervention_name>
    <arm_group_label>Caucasian Subjects - Dose 2 BG00012</arm_group_label>
    <arm_group_label>Japanese Subjects - Dose 2 BG00012</arm_group_label>
    <arm_group_label>Chinese Subjects - Dose 2 BG00012</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must give written informed consent and any authorizations required by local law

          -  All subjects must practice effective contraception during the study and be willing and
             able to continue contraception for 30 days after their last dose of study treatment.

        Exclusion Criteria:

          -  History of any clinically significant cardiac, endocrine, hematologic, hepatic,
             immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric,
             and renal, or other major disease, as determined by the Investigator.

          -  History of malignancy (subjects with basal cell carcinoma that has been completely
             excised prior to study entry remain eligible)

          -  History of severe allergic or anaphylactic reactions

          -  Known history of or positive test result for Human Immunodeficiency Virus (HIV)

          -  Serious infection (e.g., pneumonia, septicemia) within 2 months prior to Screening.

          -  Female subjects who are pregnant or currently breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

